Drug – bio-affecting and body treating compositions – Plant material or plant extract of undetermined constitution...
Reexamination Certificate
2009-06-02
2011-11-29
Mi, Qiuwen (Department: 1655)
Drug, bio-affecting and body treating compositions
Plant material or plant extract of undetermined constitution...
Reexamination Certificate
active
08067041
ABSTRACT:
The present invention provides methods for treating constipation-predominant irritable bowel syndrome comprising administering to a patient in need thereof, a polymeric proanthocyanidin composition from aCrotonspecies orCalophyllumspecies in an amount sufficient to treat constipation-predominant irritable bowel syndrome (c-IBS). Treatment of c-IBS includes the treatment of the constipation component of c-IBS as well as the pain and abdominal discomfort associated with c-IBS. In one embodiment, the polymeric proanthocyanidin compound is crofelemer. The present invention in an alternative embodiment also provides methods for treating alternating constipation-predominant/diarrhea-predominant irritable bowel syndrome.
REFERENCES:
patent: 4698360 (1987-10-01), Masquelier
patent: 4857327 (1989-08-01), Virdalm
patent: 5043160 (1991-08-01), Wursch
patent: 5211944 (1993-05-01), Tempesta
patent: 5234922 (1993-08-01), Welsh et al.
patent: 5494661 (1996-02-01), Tempesta
patent: 6281240 (2001-08-01), Schultz
patent: 7208183 (2007-04-01), Bobrowski
patent: 7235573 (2007-06-01), Verkman et al.
patent: 2004/0063695 (2004-04-01), Verkman et al.
patent: 2004/0235800 (2004-11-01), Verkman et al.
patent: 2005/0019389 (2005-01-01), Rozhon et al.
patent: 2005/0100535 (2005-05-01), Farmer et al.
patent: 2007/0104728 (2007-05-01), Olalde Rangel
patent: 1215561 (1999-05-01), None
patent: 0481396 (1995-01-01), None
patent: WO 9206695 (1992-04-01), None
patent: WO-200047062 (2000-08-01), None
Yan, The actions of rhubarb and other Chinese drugs and compound prescriptions in animal models, Zhong Yao Tong Bao 1998: 13 (8): 43-45.
Mangel et al., “Evaluation of Crofelemer in the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome (dIBS) Patients,” unpublished manuscript.
Pieters, L., “The Biologically Active Constituents of “Sangre De Drago” A Traditional South American Drug.” University of Antwerp, doctoral dissertation in the Departement Farmaceutische Wetenschappen, 1992.
Fischer et al., A novel extract SB-300 from the stem bark latex of Croton lechleri inhibits CFTR-mediated chloride secretion in human colonic epithelial cells. Journal of Ethnopharmacology, (2004) vol. 93, No. 2/3, pp. 351-357.
U.S. National Library of Medicine and National Institutes of Health website, <<www.nlm.nih.gov/medlineplus/ druginfo/medmaster/a682280.html>>, entry for loperamide, last revised-Jan. 1, 2002, downloaded from internet on Aug. 27, 2007.
Wood, AJJ, “Irritable Bowel Syndrome,” New England Journal of Medicine, Nov. 27, 2003, vol. 349, issue 22, pp. 2136-2146.
Jailwala et al., “Pharmacologic Treatment of the Irritable Bowel Syndrome: A Systematic Review of Randomized, Controlled Trials,” Ann Intern Med, 2000, vol. 133, pp. 136-147.
Cremonini et al., “Diagnostic and Therapeutic Strategies in the Irritable Bowel Syndrome,” Minerva Med, 2004, vol. 95, No. 5, pp. 427-441.
DiCesare et al., “A double blind, randomized, placebo-controlled study of SP-303 (Provir) in the symptomatic treatment of acute diarrhea among travelers to Jamaica and Mexico,” Am. J. Gastroenterol., vol. 97, issue 10, pp. 2585-2588, Oct. 2002.
Miller et al., “Inhibition of Neurogenic Inflammation by the Amazonian Herbal Medicine Sangre de Grado,” Journal of Investigative Dermatology, vol. 117, No. 3, pp. 725-730, Sep. 2001.
Hovdenak, N., Scandinavian Journal of Gastroenterology, vol. 22, supp. 130, pp. 81-84, 1987.
Efskind, P., et al., Scandinavian Journal of Gastroenterology, vol. 31, No. 5, pp. 463-468, May 1996.
Miller, M. et al., Am. J. Physiol Gasrointest Liver Physiol., vol. 279, pp. G192-G200, 2000.
Lavo, B., et al., Scandinavian Journal of Gastroenterology, vol. 22, supp. 130, pp. 77-80, 1987.
Cann, P., et al., Digestive Diseases and Sciences, vol. 29, No. 3, pp. 239-247, Mar. 1984.
Black, “The Prophylaxis and Therapy of Secretory Diarrhea,” Medical Clinics of North America 66(3): 611-621, 1982.
Castelli and Carosi, 1995, “Epidemiology of Traveler's Diarrhea,” Chemotherapy 41(suppl. 1): 20-32.
Chen et al., “Studies on the Anti-Tumor, Anti-Bacterial, and Wound-Healing Properties of Dragon's Blood,” Planta Med. 1994, 60:541-545.
Driesen et al., 1993, “Studies on Preweaning Piglet Diarrhoea,” Australian Veterinary Journal, 70(7): 259-262.
DuPont, 1995, “Pathogenesis of Traveler's Diarrhea,” 41(suppl 1): 33-39.
DuPont, 1995, “Traveler's Diarrhea,” Infections of the Gastrointestinal Tract, (Edited by M. Blaser et al., Raven Press, Ltd., New York): 299-310.
Gabriel et al., 1994, “Cystic Fibrosis Heterozygote Resistance to Cholera Toxin in the Cystic Fibrosis Mouse Model,” Science 266: 107-109.
Gabriel et al., 1993, “CFTR and Outward Rectifying Chloride Channels are distinct Proteins with a Regulatory Relationship,” Nature 363:263-266.
Galvez et al., 1991, “Antidiarrhoeic Activity ofSclerocarya birreaBark Extract and its Active Tannin Constitutent in Rats,” Phyt. Res. 5:276-278.
Galvez et al., 1993, “Pharmacological Activity of a Procyanidin Isolated fromSclerocarya birreaBark: Antidiarrhoel Activity and Effects on Isolated Guinea-pig ileum,” Phyt. Res. 7:25-28.
Gracey, 1986, “Bacterial Diarrhoea,” Clinics in Gasteronerology 15(1): 21-37.
Gutzmiller et al., 1996, “Effects of Oral Lactose and Xylose Loads on Blood Glucose, Galactose, Xylose, and Insulin Values in Healthy Calves and Calves with Diarrhea,” AJVR 57(4): 560-563.
Harris, 1988, “Review of Selected Bacterial Enterotoxins and their Role in Gastroenteritis,” 18: 102-108.
Holland, 1990, “Some Infectious Causes of Diarrhea in Young Farm Animals,” Clinical Microbiology Reviews 3(4): 345-375.
HÖr et al., 1995, “Inhibition of Intestinal Chloride Secretion by Proanthocyanidins from Guazuma ulfmifolia,” Planta Med. 61: 208-212.
Hör et al., 1996, “Proanthocyanidin Polymers with Antisecretory Activity and Proanthocyanidin Oligomers from Guazuma Ulmifolia Bark,” Phytochemistry 42(1): 109-119.
König et al., 1994, “Ellagitannins and Complex Tannins fromQuercus petraeaBark,” J. Nat. Prod. 57:1411-1415.
Mouricout, 1991, “Swine and Cattle EnterotoxigenicEscherichia coli-mediated Diarrhea. Development of Therapies Based on Inhibition of Bacteria-Host Interactions,” Eur. J. Epidemiol. 7(6): 588-604.
Newman et al., 1987, “High-Resolution C NMR Studies of Proanthocyanidin Polymers (Condensed Tannins),” Nag. Res. Comm. 25: 118-124.
Onwukaeme and Lot, 1991, “A Pharmacological Evaluation of Baphia nitida Lodd (Leguminosae) Ethanolic Extracts on Rats and Mice,” Phytotherapy Res. 5:254-257.
Onwukaeme and Anuforo, 1993, “Phytochemical and Pharmacological Studies on Pycanthus angolensis (Welw) Warb (Myristicaceae),” Discovery and Innovation 5:317-322.
Oooms and Degryse, 1986, “Pathogenesis and Pharmacology of Diarrhea,” Veterinary Research Communications 10: 355-397.
Pallenbach et al., 1993, “Proanthocyanidins fromQuercus petraeaBark,” Planta Med. 59: 264-268.
Persinos et al., 1979, “Errors in Chlorothiazide Bioavailability Estimates Based on a Bratton-Marshall Colorimetric Method for Chlorothiazide in Urine,” J. Pharm. Sci. 68: 124.
Sethi, 1977, “Inhibition of RNA-Directed DNA Polymerase Activity of RNA Tumor Viruses by Taspine,” Canadian J. Pharm. Sci. 12: 7-9.
Silverstein, 1989, “Procyandin from Black Bean (Phaseolus Vulgars): Effects on Transport of Sodium, Chloride, Glucose, and Alanine in the rat ileum,” Washington State University (Dissertation).
Strombeck, 1995, “Diagnosis and Treatment of Chronic Diarrhea,” The Veterinary Quarterly 17(Suppl. I): S12-S15.
Tanaka et al., 1992, “Tannins and Related Compounds. CXVI. Six New Complex Tannins, Guajavins, Psidinins and Psiguavin from the Bark
Quart Barry D.
Rosenbaum David P.
Clarke Marcie B.
McCarter & English LLP
Mi Qiuwen
Napo Pharmaceuaticals, Inc.
Sparks Jonathan M.
LandOfFree
Method for treatment of constipation-predominant irritable... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treatment of constipation-predominant irritable..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treatment of constipation-predominant irritable... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4311356